ERBB2 and breast carcinoma: Plasma samples were collected from HER2-positive breast cancer patients receiving pyrotinib treatment (manufactured by Jiangsu Hengrui Pharmaceuticals Co., Ltd., National Drug Approval No. H20180012; 80 mg tablets, administered once daily at doses ranging from 240 to 400 mg).